Verve Therapeutics Inc (VERV) concluded trading on Thursday at a closing price of $7.99, with 3.87 million shares of worth about $30.93 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 3.77% during that period and on January 23, 2025 the price saw a gain of about 2.44%. Currently the company’s common shares owned by public are about 84.64M shares, out of which, 63.10M shares are available for trading.
Stock saw a price change of 45.54% in past 5 days and over the past one month there was a price change of 54.84%. Year-to-date (YTD), VERV shares are showing a performance of 41.67% which decreased to -35.51% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.30 but also hit the highest price of $19.34 during that period. The average intraday trading volume for Verve Therapeutics Inc shares is 1.62 million. The stock is currently trading 30.31% above its 20-day simple moving average (SMA20), while that difference is up 35.15% for SMA50 and it goes to 36.69% higher than SMA200.
Verve Therapeutics Inc (NASDAQ: VERV) currently have 84.64M outstanding shares and institutions hold larger chunk of about 76.26% of that.
The stock has a current market capitalization of $676.47M and its 3Y-monthly beta is at 1.78. It has posted earnings per share of -$2.46 in the same period. It has Quick Ratio of 13.05 while making debt-to-equity ratio of 0.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VERV, volatility over the week remained 13.86% while standing at 10.10% over the month.
Analysts are in expectations that Verve Therapeutics Inc (VERV) stock would likely to be making an EPS of -0.67 in the current quarter, while forecast for next quarter EPS is -0.74 and it is -2.91 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.81 which is -0.51 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.69 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 22.10% while it is estimated to decrease by -15.44% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on April 08, 2024 offering a Buy rating for the stock and assigned a target price of $15 to it. Coverage by Canaccord Genuity stated Verve Therapeutics Inc (VERV) stock as a Buy in their note to investors on April 13, 2023, suggesting a price target of $29 for the stock. On February 01, 2023, Cantor Fitzgerald Initiated their recommendations, while on December 15, 2022, Goldman Initiated their ratings for the stock with a price target of $13. Stock get a Neutral rating from Credit Suisse on October 06, 2022.
